Pharmacological Treatment for Heart Failure: A View From the Brain

Systolic heart failure is a feed‐forward phenomenon with devastating consequences. Impaired cardiac function is the initiating event, but central nervous system mechanisms activated by persistent altered neural and humoral signals from the periphery play an important sustaining role. Animals with ex...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2009-08, Vol.86 (2), p.216-220
Main Authors: Felder, RB, Yu, Y, Zhang, Z‐H, Wei, S‐G
Format: Article
Language:English
Subjects:
Aldosterone - metabolism
Angiotensins - drug effects
Angiotensins - metabolism
Animals
Biological and medical sciences
Blood-Brain Barrier
Brain - drug effects
Brain - metabolism
Brain - physiopathology
Cardiology. Vascular system
Cardiovascular Agents - pharmacology
Cardiovascular Agents - therapeutic use
Cell Communication
Cytokines - metabolism
Drug Carriers
Drug Design
Heart
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Heart Failure, Systolic - drug therapy
Heart Failure, Systolic - metabolism
Heart Failure, Systolic - physiopathology
Humans
Inflammation - metabolism
Medical sciences
Pharmacology. Drug treatments
Sympathetic Nervous System - drug effects
Sympathetic Nervous System - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systolic heart failure is a feed‐forward phenomenon with devastating consequences. Impaired cardiac function is the initiating event, but central nervous system mechanisms activated by persistent altered neural and humoral signals from the periphery play an important sustaining role. Animals with experimentally induced heart failure have neurochemical abnormalities in the brain that, when manipulated, profoundly affect sympathetic drive, volume regulation, and cardiac remodeling—critical determinants of outcome. This brief review explores recent studies that provide a strong rationale for the development of pharmaceutical agents that target central nervous system abnormalities in heart failure. Clinical Pharmacology & Therapeutics (2009); 86, 2, 216–220 doi:10.1038/clpt.2009.117
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2009.117